SCHEMBL3754614

SCHEMBL3754614

CCOc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1[N+](=O)[O-]

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TUBB1 Q9H4B7 12/20 0.81
TUBB4A P04350 4/20 0.81
TUBB P07437 4/20 0.81
TUBA3C P0DPH7 4/20 0.81
TUBA1B P68363 4/20 0.81
TUBA4A P68366 4/20 0.81
TUBB4B P68371 4/20 0.81
TUBB3 Q13509 4/20 0.81
TUBB2A Q13885 4/20 0.81
TUBB8 Q3ZCM7 4/20 0.81
TUBA3E Q6PEY2 4/20 0.81
TUBA1A Q71U36 4/20 0.81
TUBA1C Q9BQE3 4/20 0.81
TUBB6 Q9BUF5 4/20 0.81
TUBB2B Q9BVA1 4/20 0.81
PTGS2 P35354 2/20 0.60
CYP19A1 P11511 2/20 0.52
PDCD1 Q15116 1/20 0.50
CD274 Q9NZQ7 1/20 0.50
SLC22A2 O15244 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23671617 1.00 TUBB1 (0.81) TUBB1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL29815036 1.00 TUBB1 (0.81) TUBB1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL23671618 1.00 TUBB1 (0.81) TUBB1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL30466670 0.90 TUBB1 (1.00) TUBB1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL1764919 0.90 TUBB1 (1.00) TUBB1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL29815038 0.90 TUBB1 (1.00) TUBB1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL30063036 0.90 TUBB1 (1.00) TUBB1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL4967209 0.90 TUBB1 (1.00) TUBB1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL1764918 0.90 TUBB1 (1.00) TUBB1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL5191583 0.88 TUBB1 (0.69) TUBB1TUBB4ATUBBTUBA3CTUBA1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2065358-B1 THE PREPARTION AND THE USE OF ETHOXY COMBRETASTATINS AND THEIR PRODRUGS ZHEJIANG DADE PHARMACEUTICAL GROUP CO LTD (CN) 2015-07-08 EP claimed
US-7838706-B2 Preparation and the use of ethoxy combretastatins and their prodrugs ZHEJIANG DADE PHARMACEUTICAL GROUP CO. LTD (CN) 2010-11-23 US claimed
US-20090170956-A1 PREPARATION AND THE USE OF ETHOXY COMBRETASTATINS AND THEIR PRODRUGS ZHEJIANG DADE PHARMACEUTICAL GROUP CO. LTD (CN) 2009-07-02 US claimed
EP-2065358-A1 THE PREPARTION AND THE USE OF ETHOXY COMBRETASTATINS AND THEIR PRODRUGS Zhejiang Dade Pharmaceutical Group Co., Ltd. (CN) 2009-06-03 EP claimed
US-20250074869-A1 AMINO-COMBRETASTATIN DERIVATIVE AND USE THEREOF YIWUHUAYAO PHARMACEUTICAL TECHNOLOGY CO., LTD (CN) 2025-03-06 US disclosed
EP-4245750-A1 AMINO-COMBRETASTATIN DERIVATIVE AND USE THEREOF YIWUHUAYAO PHARMACEUTICAL TECHNOLOGY CO., LTD (CN) 2023-09-20 EP disclosed
CN-112225673-B Amino combretastatin derivative and application thereof 义乌市华耀医药科技有限公司 2022-08-02 CN disclosed
CN-112225673-A Amino combretastatin derivative and application thereof 义乌市华耀医药科技有限公司 2021-01-15 CN disclosed
EP-2065358-B1 THE PREPARTION AND THE USE OF ETHOXY COMBRETASTATINS AND THEIR PRODRUGS ZHEJIANG DADE PHARMACEUTICAL GROUP CO LTD (CN) 2015-07-08 EP disclosed
CN-103012248-B Synthesis of amino combretastatin derivative and application of amino combretastatin derivative as oral antitumour drug ZHEJIANG DADE PHARMACEUTICAL GROUP CO LTD 2014-11-05 CN disclosed
EP-2351730-B1 ETHOXY DIPHENYL ETHANE DERIVATES, PREPARATION PROCESSES AND USES THEREOF SHANGHAI ECUST BIOMEDICINE CO LTD (CN) 2014-07-30 EP disclosed
CN-103012248-A Synthesis of amino combretastatin derivative and application of amino combretastatin derivative as oral antitumour drug ZHEJIANG DADE PHARMACEUTICAL GROUP CO LTD 2013-04-03 CN disclosed
EP-2351730-A1 ETHOXY DIPHENYL ETHANE DERIVATES, PREPARATION PROCESSES AND USES THEREOF Shanghai Ecust Biomedicine Co., Ltd (CN) 2011-08-03 EP disclosed
US-7838706-B2 Preparation and the use of ethoxy combretastatins and their prodrugs ZHEJIANG DADE PHARMACEUTICAL GROUP CO. LTD (CN) 2010-11-23 US disclosed
US-7838706-B2 Preparation and the use of ethoxy combretastatins and their prodrugs ZHEJIANG DADE PHARMACEUTICAL GROUP CO. LTD (CN) 2010-11-23 US disclosed
US-20090170956-A1 PREPARATION AND THE USE OF ETHOXY COMBRETASTATINS AND THEIR PRODRUGS ZHEJIANG DADE PHARMACEUTICAL GROUP CO. LTD (CN) 2009-07-02 US disclosed
US-20090170956-A1 PREPARATION AND THE USE OF ETHOXY COMBRETASTATINS AND THEIR PRODRUGS ZHEJIANG DADE PHARMACEUTICAL GROUP CO. LTD (CN) 2009-07-02 US disclosed
EP-2065358-A1 THE PREPARTION AND THE USE OF ETHOXY COMBRETASTATINS AND THEIR PRODRUGS Zhejiang Dade Pharmaceutical Group Co., Ltd. (CN) 2009-06-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250074869-A1 AMINO-COMBRETASTATIN DERIVATIVE AND USE THEREOF TUBB3, TUBB6, TUBA3C TUBB1 7/4885TUBB4A 10/4885TUBB 8/4885
US-20090170956-A1 PREPARATION AND THE USE OF ETHOXY COMBRETASTATINS AND THEIR PRODRUGS PHOSPHO1, TUBB3, TYMP TUBB1 5/4885TUBB4A 10/4885TUBB 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.